The Change of Bone Markers After Low Dose Alendronate in Postmenopausal Women With Bone Loss
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
High bone turnover with the bone resorption exceeding bone formation is a major mechanism of
postmenopausal osteoporosis. Therefore, inhibition of bone resorption is a rational approach
for the prevention. The Objective of the current study was to determine the short-term
efficacy of once-weekly low dose alendronate in the prevention of bone loss in early
postmenopausal Korean women with moderate bone loss via bone turnover markers.
This study was a 12-week, randomized, double-blind clinical trial compared the effects of
placebo with alendronate 20 mg once weekly. All subjects received supplemental calcium 600 mg
and vitamin D 400 IU daily. Fifty two postmenopausal women (the ages between 50-65 year) with
lumbar spine BMD at least 2.0 SD below the peak young adult mean were recruited at Eulji
University Hospital, Daejeon, Korea. BMD was measured by DXA at baseline and serum alkaline
phosphatase, osteocalcin and C-terminal telopeptide of type I collagen was measured at
baseline and 12 weeks after treatment.